Sana Biotechnology, Inc. (SANA) Financial Ratios
7 years of historical data (2018–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
3.35
↑+44% vs avg
5yr avg: 2.32
30Y Low1.5·High3.5
ROE
↑
-99.2%
↓+11% vs avg
5yr avg: -111.7%
30Y Low-232%·High-44%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SANA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Sana Biotechnology, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $955M | $376M | $794M | $744M | $2.6B | — | — | — |
| Enterprise Value | $921M | $343M | $764M | $675M | $2.4B | — | — | — |
| P/E Ratio → | -3.14 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 3.35 | 1.50 | 2.76 | 1.49 | 3.54 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SANA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
SANA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -99.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -99.2% | -99.2% | -72.0% | -43.9% | -231.6% | — | — | — |
| ROA | -50.0% | -50.0% | -40.8% | -27.6% | -38.3% | -49.8% | -58.2% | -38.6% |
| ROIC | -86.1% | -86.1% | -63.8% | -40.2% | -476.6% | — | — | — |
| ROCE | -57.0% | -57.0% | -48.4% | -31.3% | -41.3% | -29.4% | -65.9% | -25.3% |
SANA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $128M exceeds total debt of $94M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.38 | 0.38 | 0.36 | 0.22 | 0.15 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.13 | -0.10 | -0.14 | -0.20 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
Net cash position: cash ($128M) exceeds total debt ($94M)
SANA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Sana Biotechnology, Inc.'s current ratio of 3.54x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 3.99x to 3.54x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.54 | 3.54 | 3.31 | 3.99 | 5.62 | 12.22 | 7.47 | 18.26 |
| Quick Ratio | 3.54 | 3.54 | 3.31 | 3.99 | 5.62 | 12.22 | 7.47 | 18.26 |
| Cash Ratio | 3.36 | 3.36 | 3.18 | 3.80 | 5.55 | 12.03 | 7.19 | 17.16 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
SANA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Sana Biotechnology, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $231M | $195M | $188M | $166M | $188M | $187M | $187M |
Peer Comparison
Compare SANA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SANAYou | $955M | -3.1 | — | — | — | — | -99.2% | -86.1% | — |
 FATE | $264M | -2.0 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 CRSP | $5B | -8.5 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $3B | -39.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 EDIT | $311M | -1.8 | — | — | — | — | -198.1% | — | — |
 NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
 ALNY | $40B | 130.0 | 71.9 | 86.9 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 IONS | $13B | -32.3 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 RCKT | $418M | -1.9 | — | — | — | — | -60.3% | -63.2% | — |
 SGMO | $38M | -0.4 | — | — | 100.0% | -179.9% | -185.4% | -178.8% | — |
 ILMN | $22B | 26.2 | 20.1 | 23.3 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See SANA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SANA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SANA vs FATE
Side-by-side business, growth, and profitability comparison vs Fate Therapeutics, Inc..
Start ComparisonSANA — Frequently Asked Questions
Quick answers to the most common questions about buying SANA stock.
What is Sana Biotechnology, Inc.'s P/E ratio?
Sana Biotechnology, Inc.'s current P/E ratio is -3.1x. This places it at the 50th percentile of its historical range.
What is Sana Biotechnology, Inc.'s ROE?
Sana Biotechnology, Inc.'s return on equity (ROE) is -99.2%. The historical average is -111.7%.
Is SANA stock overvalued?
Based on historical data, Sana Biotechnology, Inc. is trading at a P/E of -3.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.